Base de dados : LILACS
Pesquisa : D12.776.124.486.485.114.323.204 [Categoria DeCS]
Referências encontradas : 255 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 26 ir para página                         

  1 / 255 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-717034
Autor: Zuñiga Zambrano, Yenny Carolina; Vásquez, Rafael.
Título: Trastornos psiquiátricos en pacientes pediátricos con lupus eritematoso sistémico en un hospital de referencia / Psychiatric Disorders in Pediatric Patients With Systemic Lupus Erythematosus in a Reference Hospital
Fonte: Rev. colomb. psiquiatr;43(2):73-79, abr. 2014. ilus, tab.
Idioma: es.
Resumo: Objetivo: Describir las manifestaciones psiquiátricas de pacientes con lupus eritematoso sistémico atendidos en la Fundación Hospital de la Misericordia. Métodos: Estudio observacional descriptivo. Se revisaron historias clínicas y paraclínicos de pacientes hospitalarios y ambulatorios (2007-2013). Se seleccionó a 39 pacientes. Se utilizó SPSS19 para el análisis estadístico. Se consideró estadísticamente significativo un valor de p < 0,05. Resultados: La media de edad era 13,7 ± 2,33 (7-17) años; el 78,9% eran mujeres. Las manifestaciones psiquiátricas fueron trastorno de ansiedad (52,6%), trastorno adaptativo y depresión (el 36,8% cada uno), psicosis (10%), trastorno conversivo (7,9%) y trastorno obsesivo compulsivo (5,3%). La puntuación SLICC media fue 2,76 ± 2,8 y la SLEDAI, 20,81 ± 20,82. Los anticuerpos antinucleares fueron positivos en el 81,25%. El 65,8% tenía diagnóstico de lupus neuropsiquiátrico, el 23,7% con crisis epilépticas, el 36,8% con cefalea, el 13,2% con accidente cerebrovascular, y vasculitis, corea y meningitis (el 5,3% cada una). El tiempo promedio desde el diagnóstico fue 20,47 ± 22,2 meses, mínimo para trastorno adaptativo (15 meses) y máximo para trastorno conversivo (seudocrisis) (31 meses). Los pacientes con psicosis presentaron las más altas puntuaciones de actividad lúpica (35,5 ± 16,21 frente a 19,08 ± 13,72; p = 0,032) y daño por la enfermedad (SLICC, 4,25 ± 4,03 frente a 2,58 ± 2,67; p = 0,27) en comparación con otros diagnósticos. Conclusiones: Las manifestaciones psiquiátricas más frecuentes fueron trastorno de ansiedad, adaptativo y depresión, con frecuencias mayores que lo reportado en otras poblaciones. Se demostró actividad lúpica principalmente en los pacientes con psicosis.

Objective: To describe the psychiatric manifestations in pediatric patients with systemic erythematous lupus seen in the Fundación Hospital de la Misericordia. Methods: Observational descriptive study. Medical charts and test results of inpatients and outpatients between 2007 and2013 were reviewed; 39 patients were selected. SPSS 19 was used for statistical analysis. Statistical significance was considered with P= .05. Results: Mean age was 13.7 (2.33), with 78.9% female. The most frequent psychiatric manifestation was anxiety (52.6%), followed by adjustment disorder and depression (36.8% each one), psychosis (10%), conversion disorder (7.9%), and obsessive compulsive disorder (5.3%). The mean SLICC score was 2.76 (2.8), and the mean SLEDAI score was 20.81 (20.82). Antinuclear antibodies were positive in 81.25%. Neuropsychiatric lupus was diagnosed in 65.8% of patients; seizures were observed in 23.7%, headache in 36.8%, stroke in 13.2%, vasculitis, chorea 5.3%, and meningitis 5.3% of patients. The mean time from lupus diagnosis was 20.47 (22.2) months, with the shortest period for adjustment disorder and the longest period in patients with conversion disorder (pseudo-seizures) being 15 months and 31 months, respectively. The highest SLEDAI score was in patients with psychosis (35.5 [16.21] vs 19.08 [13.72]; P = .032), and also the highest disease damage (SLICC, 4.25 [4.03] vs 2.58 [2.67]; P = .27) in comparison with the other manifestations. Conclusions: The most frequent psychiatric manifestations were anxiety, depression, and adjustment disorder, with a higher frequency than other studies, and with lupus activity principally in patients with psychosis.
Descritores: Pacientes
Transtornos Psicóticos
Lúpus Eritematoso Sistêmico
-Ansiedade
Vasculite
Transtornos de Adaptação
Anticorpos Antinucleares
Análise Estatística
Depressão
Transtornos Mentais
Transtorno Obsessivo-Compulsivo
Limites: Humanos
Feminino
Criança
Responsável: CO78 - Asociación Colombiana de Psiquiatría


  2 / 255 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Id: biblio-1093588
Autor: Kokuina, Elena; Florian González, Yunier; Marrero-Hernandez, Delsy; Peña Cabrera, Yahima; Estévez del Toro, Miguel.
Título: Optimización del algoritmo diagnóstico de anticuerpos antinucleares / Optimization of the diagnostic algorithm of antinuclear antibodies
Fonte: Rev. cuba. med;57(4):e403, oct.-dic. 2018. tab, graf.
Idioma: es.
Resumo: Introducción: La prueba de anticuerpos antinucleares es una poderosa herramienta en el diagnóstico de las enfermedades reumáticas. Los anticuerpos antinucleares se determinan en el laboratorio por un algoritmo o secuencia que se inicia con prueba de cribado y sigue con la identificación de las especificidades antinucleares más comunes. Pero, ¿cómo interpretar los resultados discordantes entre los dos niveles de estudio de anticuerpos antinucleares? Objetivo: Determinar las especificidades antinucleares menos frecuentes en pacientes positivos de cribado de ANA y negativos de las especificidades más comunes. Métodos: Estudio prospectivo de 88 pacientes consecutivos remitidos para la detección rutinaria de ANA con resultado positivo de cribado por ensayo inmuno-adsorbente ligado a enzima (ELISA) pero negativo de anticuerpos anti-ADN de doble cadena (dc, IgG) y anti-antígenos nucleares extraíbles comunes (ENAc). Las muestras séricas correspondientes fueron evaluadas por inmunofluorescencia indirecta sobre células de carcinoma epidermoide laríngeo humano (IFI-HEp-2) y por ELISA para la detección individual de ANA específicos. Resultados: La prueba de ANA por IFI/HEp-2 resultó positiva en 56/88 (63,6 por ciento) y las especificidades antinucleares se detectaron en 57/88 (64,8 por ciento) muestras, en el orden decreciente de Anti-Nucs: 16/88 (18,2 por ciento); anti-centrómero (CENP-B): 15/88 (17,0 por ciento); -histona: 15/88 (17 por ciento); -PM/Scl: 13/88 (14,8 por ciento); -ADNsc: 11/88 (12,5 por ciento) y -ENAc individuales: 8/88 (9,1 por ciento). La sensibilidad de la IFI-HEp-2 para las especificidades antinucleares fue de 0,83 (IC95 por ciento: 0,72-0,93). De los pacientes negativos de subserología (26/31), 83,9 por ciento no tenían antecedentes de enfermedad reumática asociada a ANA. Conclusiones: La mayoría de los pacientes con resultados discordantes entre el primer y segundo nivel de ANA fueron positivos de especificidades antinucleares menos comunes, pero de reconocido valor diagnóstico(AU)

Introduction: The antinuclear antibody test is a powerful tool for diagnosing rheumatic diseases. Antinuclear antibodies are determined in the laboratory by an algorithm or sequence that starts with a screening test and continues with the identification of the most common antinuclear specificities. But how to interpret the discordant results between the two levels of study of antinuclear antibodies? Objective: To determine the less frequent antinuclear specificities in positive patients of ANA screening and negative of the most common specificities. Methods: A prospective study was done on 88 consecutive patients referred for the routine ANA screening with a positive result of screening by enzyme-linked immunosorbent assay (ELISA) but negative for anti-double-stranded DNA (dc, IgG) and common extractable anti-nuclear antigens (ENAc). The corresponding serum samples were evaluated by indirect immunofluorescence on human laryngeal epidermoid carcinoma cells (IFI-HEp-2) and by ELISA for the individual detection of specific ANA. Results: The ANA test by IFI / HEp-2 was positive in 56/88 (63.6 percent) and the antinuclear specificities were detected in 57/88 (64.8 percent) samples, in decreasing Anti-Nucs order: 16/88 (18.2 percent); anti-centromere (CENP-B): 15/88 (17.0 percent); -histona: 15/88 (17 percent); -PM / Scl: 13/88 (14.8 percent); -ADNsc: 11/88 (12.5 percent) and -ENAc individual: 8/88 (9.1 percent). The sensitivity of IFI-HEp-2 for antinuclear specificities was 0.83 (95 percent CI: 0.72-0.93). No history of rheumatic disease associated with ANA was read in (26/31) 83.9 percent patients with negative subserology. Conclusions: The majority of patients with discordant results between the first and second level of ANA were positive of less common antinuclear specificities, but of recognized diagnostic value(AU)
Descritores: Algoritmos
Anticorpos Antinucleares
-Estudos Prospectivos
Limites: Humanos
Responsável: CU1.1 - Biblioteca Médica Nacional


  3 / 255 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1011897
Autor: Aydemir, Yasemin Gul; Kocakusak, Ahmet.
Título: The evaluation of the Myxovirus Resistance 1 protein in serum and saliva to monitor disease activation in primary Sjögren's syndrome
Fonte: Clinics;74:e631, 2019. tab.
Idioma: en.
Resumo: OBJECTIVE: Primary Sjögren's syndrome (pSjS) is a chronic autoimmune disease that causes dry eye and mouth. No laboratory parameters to monitor the activation of this disease have been identified. Therefore, any possible relationships between salivary and blood myxovirus resistance 1 (MX1) and pSjS must be prospectively studied. METHODS: Thirty female patients with pSjS, 30 women with rheumatoid arthritis (RA) without secondary Sjögren's syndrome (SjS) and 28 healthy control women were enrolled in this investigation. Analyses of MX1 by the enzyme-linked immunosorbent assay (ELISA) method, SS-A (Ro) and SS-B (La) tests by the strip immunoblot method, anti-nuclear antibody (ANA) tests by immunofluorescence and the measurement of serum rheumatoid factor (RF), C3, C4, immunoglobulin A (IgA), immunoglobulin M (IgM), and immunoglobulin G (IgG) were performed. RESULTS: The serum level of MX1 in patients without Raynaud phenomenon was higher than in those with Raynaud phenomenon (p:0.029, p<0.05, statistically significant). There was a statistically significant positive association between hemoglobin levels and MX1 serum levels. No statistically significant association was found among the other parameters. Low MX1 levels were shown to be associated with both a low disease activity score based on the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) and hydroxychloroquine use in all patients. CONCLUSION: MX1 levels have a considerable impact on the assessment of the disease activity in SjS. We believe that more-comprehensive studies should be performed on patients with pSjS who do not use hydroxychloroquine to prove this relationship and that MX1 levels should be used as a routine marker for the assessment of pSjS disease activity. Further studies are needed to create awareness of the role that MX1 has in the diagnosis of pSjS, which may help to uncover novel pathways for new therapeutic modalities.
Descritores: Saliva/química
Isotipos de Imunoglobulinas/sangue
Síndrome de Sjogren/metabolismo
Proteínas de Resistência a Myxovirus/imunologia
-Imunoglobulina G
Imunoglobulina M/sangue
Ensaio de Imunoadsorção Enzimática
Biomarcadores/análise
Síndrome de Sjogren/diagnóstico
Síndrome de Sjogren/imunologia
Anticorpos Antinucleares/sangue
Limites: Humanos
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  4 / 255 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: biblio-1239150
Autor: Repka, João Carlos D; Skare, Thelma L; Salles Júnior, Guataçara; Paul, Gustavo Marchesini.
Título: Anticorpo anticardiolipina em pacinetes com mal de Hansen / Anticardiolipin antibodies in leprosy patients.
Fonte: s.l; s.n; jan.-fev. 2001. 6 p. tab, graf.
Idioma: pt.
Descritores: Anticorpos Antifosfolipídeos
Anticorpos Antinucleares
Autoanticorpos
Hanseníase
Responsável: BR191.1 - Biblioteca e Centro de Documentação Luiza Keffer
[{"text": "BR191.1", "_a": "08733/s"}]


  5 / 255 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Andrade, Luís Eduardo Coelho
Texto completo
Id: biblio-1088624
Autor: Cruvinel, Wilson de Melo; Andrade, Luis Eduardo Coelho; von Mühlen, Carlos Alberto; Dellavance, Alessandra; Ximenes, Antônio Carlos; Bichara, Carlos David; Bueno, Cleonice; Mangueira, Cristóvão Luis Pitangueira; Bonfá, Eloísa; Brito, Fabiano de Almeida; Flumian, Fernanda Bull; Silva, Glaucielen Gomes da; Rêgo, Jozelia; Anjos, Lisiane Maria Ericoni dos; Slhessarenko, Natasha; Pasoto, Sandra Gofinet; Neves, Suzane Pretti Figueiredo; Valim, Valéria; Santos, Wilton Silva dos; Francescantonio, Paulo Luiz Carvalho.
Título: V Brazilian consensus guidelines for detection of anti-cell autoantibodies on hep-2 cells
Fonte: Adv Rheumatol;59:28, 2019. tab, graf.
Idioma: en.
Resumo: Abstract Background: The V Brazilian Consensus for determination of autoantibodies against cellular constituents on HEp-2 cells, held in Brasilia (DF, Brazil) on August 27, 2016, discussed the harmonization between the Brazilian Consensus on ANA (BCA) guidelines and the International Consensus on ANA Patterns (ICAP) recommendations (www.anapatterns.org). Initial guidelines were formulated by the group of Brazilian experts with the purpose of guiding and enabling Brazilian clinical laboratories to adopt recommendations and to provide a common standard for national and international consensuses. Mainbody: Twenty Brazilian researchers and experts from universities and clinical laboratories representing the various geographical regions of the country participated in the meeting. Three main topics were discussed, namely the harmonization between the BCA guidelines and latest recommendations of the ICAP initiative, the adjustment of the terminology and report on HEp-2 patterns, and a reassessment of quality assurance parameters. For the three topics, our aim was to establish specific guidelines. All recommendations were based on consensus among participants. There was concrete progress in the adjustment of the BCA guidelines to match the ICAP guidelines. To a certain extent, this derives from the fact that ICAP recommendations were largely based on the algorithm and recommendations of the IV Brazilian ANA Consensus, as consistently recognized in the ICAP publications and presentations. However, although there is great overlap between the two Consensuses, there are some point divergences. These specific items were individually and extensively discussed, and it was acknowledged that in several points ICAP improved recommendations previously issued by the Brazilian ANA Consensus and these changes were readily implemented. Regarding some specific topics, the BCA panel of experts felt that the previously issued recommendations remained relevant and possibly will require further discussion with ICAP. The term anti-cell antibodies was adopted as the recommended designation, recognizing that the assay addresses antibodies against antigens in the nucleus and in other cell compartments. However, the acronym ANA HEp-2 was maintained due to historical and regulatory reasons. It was also signalized that the latest trend in ICAP is to adopt the term Indirect Immunofluorescent Assay on HEp-2 cell substrate (HEp-2 IIFA). In addition, the quality assurance strategies previously presented were ratified and emphasized. Conclusion: The V BCA edition was successful in establishing an overall harmonization with the ICAP recommendations for interpretation of the HEp-2 IIFA test, pinpointing the perspectives in filling the remaining gaps between both initiatives.
Descritores: Autoanticorpos/análise
Células Hep G2
-Anticorpos Antinucleares
Guias como Assunto/normas
Técnica Indireta de Fluorescência para Anticorpo/instrumentação
Responsável: BR1.1 - BIREME


  6 / 255 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-827992
Autor: Alves, Bruna; Zakka, Telma M; Teixeira, Manoel J; Kaziyama, Helena H; Siqueira, Jose T T; Siqueira, Silvia R. D T.
Título: Depression, sexuality and fibromyalgia syndrome: clinical findings and correlation to hematological parameters / Depressão e sexualidade na síndrome fibromiálgica: achados clínicos e correlação com parâmetros hematológicos
Fonte: Arq. neuropsiquiatr;74(11):863-868, Nov. 2016. tab, graf.
Idioma: en.
Resumo: ABSTRACT Fibromyalgia (FM) is characterized by chronic pain and comorbidities. Objective To investigate sexuality and depression in women with FM compared with controls and to correlate the findings with hematological parameters. Methods 33 women with FM and 19 healthy women were included and evaluated with the following instruments: Female Sexual Function Index, Beck Inventory, Visual Analogue Scale, medical history and laboratory exams. Results The prevalence of sexual dysfunction (P = 0.007) and depression (P < 0.001) were higher in the study group than in the control group; they were positively correlated (P = 0.023). The study group showed lower serum concentrations of testosterone, free T4, antinuclear factor, and lower blood hemoglobin and hematocrit. Conclusions FM was associated with high scores of sexual dysfunction and depression, and there were correlations with hematological parameters. We suggest the involvement of immune-inflammatory mediators and FM, which need further investigation to understand their role in FM syndrome and its comorbidities.

RESUMO Fibromialgia (FS) é caracterizada por dor e comorbidades. Objetivo investigar depressão e sexualidade em mulheres com FS comparadas a controles, e correlacionar os achados com parâmetros hematológicos. Métodos 33 mulheres com FS e 19 controles saudáveis foram incluídas e avaliadas através dos seguintes instrumentos: Índice de Função Feminina Sexual, Inventário de Beck, escala visual analógica, história médica e exames laboratoriais. Resultados A prevalência de disfunção sexual (P = 0,007) e depressão (P < 0,001) foram maiores no grupo de estudo do que nos controles; também houve correlação positiva (P = 0,023). O grupo de estudo apresentou menor concentração sérica de testosterona, T4 livre, fator antinuclear e menos concentração de hemoglobina e hematócrito. Conclusões A FS associou-se com altos índices de disfunção sexual e depressão, e houve correlação com os parâmetros hematológicos estudados. Sugere-se o envolvimento de mediadores imuno-inflamatórios na FS, que necessita de maior investigação para a compreensão dos mecanismos tanto na FS e quanto em suas comorbidades.
Descritores: Disfunções Sexuais Fisiológicas/complicações
Fibromialgia/complicações
Depressão/complicações
-Testosterona/sangue
Tiroxina/sangue
Hemoglobinas/análise
Fibromialgia/fisiopatologia
Fibromialgia/sangue
Anticorpos Antinucleares/sangue
Inquéritos e Questionários
Disfunções Sexuais Psicogênicas/complicações
Hematócrito
Limites: Humanos
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  7 / 255 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Corrente, José Eduardo
Texto completo
Id: biblio-1088655
Autor: Miguel, Daniele Faria; Terreri, Maria Teresa; Pereira, Rosa Maria Rodrigues; Bonfá, Eloisa; Silva, Clovis Artur Almeida; Corrente, José Eduardo; Magalhaes, Claudia Saad.
Título: Comparison of urinary parameters, biomarkers, and outcome of childhood systemic lupus erythematosus early onsetlupus nephritis
Fonte: Adv Rheumatol;60:10, 2020. tab.
Idioma: en.
Projeto: FAPESP; . CNPq.
Resumo: Abstract Background: Urinary parameters, anti-dsDNA antibodies and complement tests were explored in patients with childhood-Systemic Lupus Erythematosus (cSLE) early-onset lupus nephritis (ELN) from a large multicenter cohort study. Methods: Clinical and laboratory features of cSLE cases with kidney involvement at presentation, were reviewed. Disease activity parameters including SLEDAI-2 K scores and major organ involvement at onset and follow up, with accrued damage scored by SLICC-DI, during last follow up, were compared with those without kidney involvement. Autoantibodies, renal function and complement tests were determined by standard methods. Subjects were grouped by presence or absence of ELN. Results: Out of the 846 subjects enrolled, mean age 11.6 (SD 3.6) years; 427 (50.5%) had ELN. There was no significant difference in the ELN proportion, according to onset age, but ELN frequency was significantly higher in non-Caucasians (p = 0.03). Hematuria, pyuria, urine casts, 24-h proteinuria and arterial hypertension at baseline, all had significant association with ELN outcome (p < 0.001). With a similar follow up time, there were significantly higher SLICC-DI damage scores during last follow up visit (p = 0.004) and also higher death rates (p < 0.0001) in those with ELN. Low C3 (chi-square test, p = 0.01), but not C3 levels associated significantly with ELN. High anti-dsDNA antibody levels were associated with ELN (p < 0.0001), but anti-Sm, anti-RNP, anti-Ro, anti-La antibodies were not associated. Low C4, C4 levels, low CH50 and CH50 values had no significant association. High erythrocyte sedimentation rate (ESR) was associated with the absence of ELN (p = 0.02). Conclusion: The frequency of ELN was 50%, resulting in higher morbidity and mortality compared to those without ELN. The urinary parameters, positive anti-dsDNA and low C3 are reliable for discriminating ELN.(AU)
Descritores: Lúpus Eritematoso Sistêmico/fisiopatologia
-Complemento C3
Complemento C4
Biomarcadores
Anticorpos Antinucleares
Estudos de Coortes
Limites: Humanos
Tipo de Publ: Estudo Comparativo
Responsável: BR1.1 - BIREME


  8 / 255 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1122377
Autor: Wainstein G, Eduardo.
Título: Laboratorio en reumatología / Laboratory in rheumatology
Fonte: Rev. Méd. Clín. Condes;23(4):371-376, jul. 2012. tab.
Idioma: es.
Resumo: La reumatología es una subespecialidad de la medicina interna que estudia y trata pacientes con problemas músculo esqueléticos, así como también enfermedades autoinmunes que comprometen el mesenquima y diferentes órganos, teniendo en común un rol patogénico del sistema inmune. El laboratorio juega un papel importante en el proceso diagnóstico de estas condiciones. Sin embargo, a pesar del progreso y refinamiento de algunos exámenes, la baja sensibilidad y especificidad que muchos de ellos tienen, hacen que la interpretación sea ocasionalmente muy difícil. En este artículo se revisan algunas características de los exámenes más comúnmente usados en reumatología, así como su sensibilidad y especificidad en el diagnóstico de estas enfermedades. Ya que la correcta interpretación de un examen requiere una compresión de conceptos estadísticos subyacentes, se revisan en forma muy somera algunos aspectos de ellos. Como conclusión, se remarca la necesidad de cuidar la interpretación de estos resultados, para evitar lo más que se pueda el costo económico, el stress psicológico y el problema médico derivado de la mala interpretación de estos exámenes.

Rheumatology is a medical subspecialty that takes care of some non traumatic musculoskeletal problems as well as many autoimmune diseases that involves the integuments and different organs, having as a common issue a pathogenic role of the immune system. Laboratory plays an important role in the diagnosis process of these conditions. However, despite the progress and refinement of some test, lack sensitivity and specificity makes interpretation of them occasionally quite difficult. Some characteristic, disease association as well as sensitivity and specificity are reviewed here for the most common rheumatic test. Since part of a correct interpretation of a test, needs an understanding of statistical principles underneath it, in a very simple way some of them are also considered in this review. As a conclusion, an underscoring of the need to process cautiously the rheumatic test results is made, to avoid as much as it can, unnecessary test and the burden both economically, psychological and medically an incorrect diagnosis, based on a misinterpretation of a test.
Descritores: Reumatologia/métodos
Testes Imunológicos/métodos
Doenças Reumáticas/diagnóstico
Doenças Reumáticas/imunologia
Técnicas de Laboratório Clínico/métodos
-Fator Reumatoide
Reumatologia/estatística & dados numéricos
Biomarcadores
Chile
Anticorpos Antinucleares
Teorema de Bayes
Síndrome Antifosfolipídica
Anticorpos Anticitoplasma de Neutrófilos
Limites: Humanos
Responsável: CL1.1 - Biblioteca Central


  9 / 255 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: biblio-1157400
Autor: Sánchez Adriana; Hernández Nelia; Chiodi Daniela; Berrueta Joaquín; Robaina Gabriela; Pollio Carmen; Mescia Germán.
Título: Cirrosis biliar primaria: aspectos clinico- epidemiológicos en una población uruguaya / [Primary biliary cirrhosis: clinical and epidemiological features in an Uruguayan population].
Fonte: Acta gastroenterol. latinoam;43(4):288-93, 2013 Dec.
Idioma: es.
Resumo: INTRODUCTION: Primary biliary cirrhosis (PBC) is a chronic cholestatic, autoimmune, liver disease produced by inflammation and destruction of the interlobular bile ducts. It is more frequent among female patients and is usually diagnosed in the fifth decade of life. OBJECTIVE: Our objective was to describe the clinical and epidemiological characteristics of patients with PBC in Uruguay. MATERIAL AND METHODS: This descriptive study included patients from 3 medical centers diagnosed with PBC in the period January 2002 to September 2011. The diagnosis was based on the presence of at least two of the following requirements: cholestasis, antimitochondrial antibodies (AMA) (or AMA subtype 2) or positive antinuclear antibodies (ANA) (anticentromere pattern) and compatible biopsy. Data recorded were sex, age, symptoms, related illness, laboratory results, images and histology at the moment of the diagnosis. RESULTS: We included 81 patients, 94

were women and the mean age was 56 years old (range: 31 to 79 years old). Symptoms were present in 59 patients (73

) and pruritus, found in 51 of them (86

), was the most frequent symptom. Positive AMA was found in 84

of cases. Histological study was available in 35 patients (43

) and 13 of them (37

) had cirrhosis. The mean survival according to the presence or absence of cirrhosis was 9.17 years (95

confidence interval: 6.79-11.56) and 10.7 years (95

confidence interval: 9.27-12.14), respectively (P = 0.03). CONCLUSIONS: Female predominance and frequent association with other autoimmune diseases were confirmed in this group. Although there was a high percentage of symptomatic and cirrhotic patients at diagnosis, only the presence of cirrhosis was associated with a lower survival.
Descritores: Cirrose Hepática Biliar
-Adulto
Anticorpos Antinucleares/sangue
Autoanticorpos/sangue
Biópsia
Cirrose Hepática Biliar/diagnóstico
Cirrose Hepática Biliar/mortalidade
Cirrose Hepática Biliar/sangue
Estimativa de Kaplan-Meier
Estudos Retrospectivos
Estudos de Coortes
Feminino
Humanos
Idoso
Masculino
Mitocôndrias/imunologia
Pessoa de Meia-Idade
Uruguai/epidemiologia
Índice de Gravidade de Doença
Tipo de Publ: Resumo em Inglês
Artigo de Revista
Responsável: AR5.1 - Centro de Gestión del Conocimiento y las Comunicaciónes


  10 / 255 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-973815
Autor: Rebelato, Jáder Buzati; Silveira, Caroline Ferreira da Silva Mazeto Pupo da; Valadão, Tainá Fabri Carneiro; Reis, Fabrício Moreira; Bazan, Rodrigo; Bazan, Silméia Garcia Zanati.
Título: Myocarditis with Cardiogenic Shock as the First Manifestation of Systemic Lupus Erythematosus / Miocardite com Choque Cardiogênico como Primeira Manifestação de Lúpus Eritematoso Sistêmico
Fonte: Arq. bras. cardiol;111(6):864-866, Dec. 2018. tab, graf.
Idioma: en.
Descritores: Lúpus Eritematoso Sistêmico/complicações
Miocardite/diagnóstico
Miocardite/etiologia
-Choque Cardiogênico/diagnóstico
Choque Cardiogênico/etiologia
Ecocardiografia
Tomografia Computadorizada por Raios X
Anticorpos Antinucleares/sangue
Lúpus Eritematoso Sistêmico/diagnóstico
Limites: Humanos
Feminino
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME



página 1 de 26 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde